samedan logo
home > ebr

European Biopharmaceutical Review


European Biopharmaceutical Review (EBR) is a journal designed to fill a unique position in scientific publishing. Published quarterly, it provides a dedicated platform of communication and information for the European biopharmaceutical market across Europe, North America & the rest of the world.

With editorial consisting of in-depth articles, case studies, meeting and report reviews written by specialists with hands-on experience in the biopharmaceutical industry, traditional multi-national pharmaceutical companies, investment houses and industry-associated governmental, economic and societal bodies. Each quarterly edition examines topical areas of importance across the board of biopharmaceutical research and development, with regular feature sections on BioBusiness Development, Research and Innovation, BioDiscovery, BioManufacturing plus special focuses on geographic or therapeutic territories.

For further information please contact:


Jasmin Collier


Max Garry 



Connect with us on Twitter: follow @EBRmagazine

Read our publications on the go in the Samedan app for iPhone and iPad. You can download issues for offline reading and our archives go as far back as 2008! Download for free on the App Store.

View the
digital version
of EBR

Featured in this issue
Understanding the mAb structure-function relationship is a crucial factor in biosimilar development, points out Dr Terry Gray at Sartorius Stedim. This way, it is possible to significantly reduce wasted resources in the manufacturing process.

Patrick Harrison at University College Cork reveals that a breakthrough has been made: stem cell and gene-editing research could accelerate finding a cure for a variety of disease-causing mutations, as well as enabling tailored treatment.
It is evident that biosimilar clinical trials are growing in popularity, with one drug in particular – rituximab – leading the way. ICON’s Kyoo Jung Shim and Petra Roos explore its ongoing development.

Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October


Industry Events

Clinical Trial Supply Southern California 2016

15-16 November 2016, San Diego, CA

Over 45% of biotechnology medicines in development today are being created by biopharmaceutical companies with major operations in California - notably San Diego which is one of the leading biotech hubs in the US.
More info >>

News and Press Releases

MRC Technology monetises royalties on cancer drug Keytruda (pembrolizumab) to expand medical research activities, with a fund managed by DRI Capital

More info >>

air transport logo


White Papers

The Flexible Factory Concept: A flexible bioprocessing platform to meet the changing needs of biomanufacturing

GE Healthcare Life Sciences

For the past several years, the biopharma industry has been buffeted by dynamic market conditions that are rapidly reshaping manufacturing requirements. These factors include: • The rise of small-market pharmaceuticals that do not require the production scale of the previous “blockbuster” drug model • Increased titers and process productivity that generate more bulk-product within a much smaller manufacturing footprint • The emergence of biosimilars and continued evolution of healthcare reform, which will increasingly pressure drug pricing and require greater cost discipline • Greater competition and shorter patent protection timelines, which will further ratchet up time-to-market pressures • Tighter capital markets that will create heightened scrutiny for all new investment projects
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement